期刊文献+

IMP3、P16蛋白、HE4、P53蛋白在卵巢浆液性肿瘤中表达及其临床意义 被引量:7

Expression of IMP3,P16 protein,HE4 and P53 protein in serous ovarian tumors and its clinical significance
下载PDF
导出
摘要 目的探究胰岛素样生长因子ⅡmRNA结合蛋白3(IMP3)、P16蛋白、人附睾蛋白4(HE4)、P53蛋白在卵巢浆液性肿瘤中表达及其临床意义。方法采用免疫组织化学法对2010年11月至2017年11月该院卵巢浆液性囊腺瘤204例(良性组),卵巢交界性浆液性肿瘤42例(交界性组),卵巢浆液性癌64例(恶性组)组织进行IMP3、P16蛋白、HE4及P53蛋白检测并分析临床病理意义。结果 IMP3、P16蛋白、HE4在良性组中的阳性表达率(15.20%、24.02%和25.00%)明显低于交界性组(54.76%、71.43%和71.43%)和恶性组(73.44%、85.94%和75.00%),差异均有统计学意义(P<0.05);P53蛋白在良性组(4.90%)和交界性组(4.76%)阳性表达率明显低于恶性组(42.19%),差异均有统计学意义(P<0.05);IMP3、HE4和P53蛋白阳性表达率在不同分化程度卵巢浆液性癌间比较,差异均具有统计学意义(P<0.05);HE4阳性表达率在盆腔淋巴结有无转移者间比较,差异具有统计学意义(P<0.05);四项指标联合检测卵巢浆液性囊腺癌灵敏度(92.19%)和特异度(96.88%),显著高于IMP3(分别为42.19%和60.94%)和P16蛋白单项检测(分别为40.62%和45.31%),差异均有统计学意义(P<0.05)。IMP3、P16蛋白、HE4和P53蛋白联合检测的受试者工作特征曲线(ROC曲线)下面积0.869显著高于各指标单独检测的曲线下面积(P<0.05);在四项指标的单独检测中,HE4的ROC曲线下面积0.816最大(P<0.05)。结论 IMP3、P16蛋白、HE4和P53蛋白联合检测能够提升临床卵巢浆液性癌的诊断率,有望成为卵巢浆液性癌检测良好指标。 Objective To observe of expression of IMP3,P16 protein,HE4 and P53 protein in serous ovarian tumors and its clinical significance.Methods 204 cares with serous cystadenomas(benign group)and 42 cares with serous borderline tumors(borderline group)and 64 cares with serous adenocarcinomas(malignant group)in a hospital from November 2010 to November 2017,which were immunohistochemical stained IMP3,P16 protein,HE4 and P53 protein,the clinical pathological significance were analyzed.Results The expression rates of IMP3,P16 protein,HE4 in benign group(15.20%,24.02%and 25.00%)was significantly lower than that in borderline group(54.76%,71.43%and 71.43%)and malignant group(73.44%,85.94%and 75.00%).The datas all had statistically significant difference(P<0.05).The expression rates of P53 protein in benign group(4.90%)and borderline group(4.76%)was significantly lower than that in malignant group(42.19%).The datas all had statistically significant difference(P<0.05).The expression rates of IMP3,HE4 and P53 protein were significantly different in different differentiation degrees serous adenocarcinomas(P<0.05).The expression rates of HE4 was significantly different in lymph node metastasis(P<0.05).The sensitivity(92.19%)and specificity(96.88%)of combined detection of four indicators of ovarian serous cystadenocarcinoma,significantly higher those the IMP3(42.19%and 60.94%)and P16 protein(40.62%and 45.31%)single examination,The dates had statistical significance(P<0.05).The area under the receiver operating characteristic curve(ROC curve)measured by IMP3,P16 protein,HE4 and P53 protein was significantly higher than the area under the curve of each index(P<0.05).In the separate detection of the four indexes,the area under the ROC curve of P53 protein was 0.816(P<0.05).Conclusion IMP3,P16 protein,HE4 and P53 protein the four joint detection can improve the diagnostic yield of serous adenocarcinomas,it is likely to be a good indicator to detect serous adenocarcinomas.
作者 赵长燕 贺红梅 邵长好 白金猛 ZHAO Changyan;HE Hongmei;SHAO Changhao;BAI Jinmeng(Department of Pathology,Qinhuangdao Maternal and Child Health Care Hospital,Qinhuangdao,Hebei 066000,China;Department of Gynaecology,Qinhuangdao Maternal and Child Health Care Hospital,Qinhuangdao,Hebei 066000,China;Department of Anesthesia,the First Hospital of Qinhuangdao,Qinhuangdao,Hebei 066000,China)
出处 《国际检验医学杂志》 CAS 2019年第6期678-682,共5页 International Journal of Laboratory Medicine
基金 秦皇岛重点研发计划科技支撑项目(201703A137)
关键词 卵巢浆液性肿瘤 P16蛋白 P53蛋白 人附睾蛋白4 胰岛素样生长因子Ⅱ mRNA结合蛋白3 serous ovarian tumors P16 protein P53 protein human epididymis protein 4 insulin-like growth factor Ⅱ mRNA-binding protein 3
  • 相关文献

参考文献12

二级参考文献139

  • 1邵汇琳,沈丹华,薛卫成,李艺,虞有智.卵巢上皮性肿瘤的临床病理特征及其细胞周期素D1和p53蛋白表达的研究[J].中华妇产科杂志,2007,42(4):227-232. 被引量:10
  • 2Shih IM,Kurman RJ.Ovarian tumorigenesis:a proposed model based on morphological and molecular genetic analysis.Am J Pathol,2004,164(5):1511-1518. 被引量:1
  • 3Gilks CB,Prat J.Ovarian carcinoma pathology and genetics:recent advances.Hum Pathol,2009,40 (9):1213-1223. 被引量:1
  • 4Malpica A,Deavers MT,Lu K,et al.Grading ovarian serous carcinoma using a two-tier system.Am J Surg Pathol,2004,28(4):496-504. 被引量:1
  • 5Scully RE.World Health Organization classification and nomenclature of ovarian cancer.Natl Cancer Inst Monogr,1975,42:5-7. 被引量:1
  • 6Armstrong DK.Relapsed ovarian cancer:challenges and management strategies for a chronic disease.Oncologist,2002,7 Suppl 5:20-28. 被引量:1
  • 7Rustin GJ,Nelstrop AE,Tuxen MK,et al.Defining progression of ovarian carcinoma during follow-up according to CA 125:a North Thames Ovary Group Study.Ann Oncol,1996,7(4):361-364. 被引量:1
  • 8Rustin GJ,Nelstrop AE,Crawford M,et al.Phase Ⅱ trial of oral altretamine for relapsed ovarian carcinoma:evaluation of defining response by serum CA125.J Clin Oncol,1997,15 (1):172-176. 被引量:1
  • 9Hill DA,Chiosea S,Jamaluddin S,et al.Inducible changes in cell size and attachment area due to expression of a mutant SWI/SNF chromatin remodeling enzyme.J Cell Sci,2004,117 (Pt24):5847-5854. 被引量:1
  • 10Gilks CB,Vanderhyden BC,Zhu S,et al.Distinction between serous tumors of low malignant potential and serous caroinonas based on global mRNA expression profiling.Gynecol Oncol,2005,96(3):684-694. 被引量:1

共引文献66

同被引文献77

引证文献7

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部